Globally, the R&D pipeline of CAR-T cells has expanded rapidly, including the exploration of new targets, such as BCMA, CD123, and CD33, as well as the expansion to new indications, such as the progression of hematological tumors to solid tumors. Here, TNFRSF17 is linked to hematopoietic and lymphoid system neoplasm.